15th Expert Committee on the Selection and Use of Essential Medicines

Outcomes of the meeting: 

The WHO Model List of Essential Medicines has been updated every two years since 1977. The current version -- the 14th list --dates from March 2005.  It contains 306 medicines.

 

Applications for inclusion, change or deletion of a medicine in the next Model List of Essential Medicines should be sent to the Secretary of the Committee whose address is below before 15 October 2006. Please note that all applications will be posted on the website for public comment and review no later than 1 November 2006.

Public comments, including letters of support on the applications may be submitted to: emlsecretariat@who.int.

All comments will also be published on the web.

   Useful information for your visit to Geneva

• Application form for inclusion, change or deletion of a medicine (89KB pdf)

• Guidelines for Guidelines (Declaration of interests for WHO Experts) (54KB doc)

• Guidelines for Guidelines (Development of WHO Treatment Guidelines: Recommended Process) (226KB pdf)

• WHO Technical Report Series 933: THE SELECTION AND USE OF ESSENTIAL MEDICINES

• 14th EML:   English    French

Open session agenda   [French version]

Comments on the draft agenda items are welcomed, especially on the applications for addition, change or deletion of medicines relating to the Model List.  Please contact:

The Secretary of the Expert Committee on the Selection and Use of Essential Medicines

Policy, Access and Rational Use

Department of Medicines Policy and Standards (PSM)
Health Technology & Pharmaceuticals

World Health Organization

20 Avenue Appia

CH-1211 Geneva 27

emlsecretariat@who.int

Please note that comments cannot be accepted after 31 January 2007 due to the large number of medicines to be reviewed and the need to prepare for the Committee Meeting.

ADULTS:

• Applications for additional formulations

• Applications for addition of medicines

• Section reviews

• Medicines for possible deletion

• Applications for re-instatement

PAEDIATRICS:

• Applications for additional formulations

• Applications for addition of medicines
   

OTHER MATTERS - Policy

Expert reviews

Other correspondence related to medicines

Late papers

• Memorandum from Dr M. Mathai, FCH/MPS/NTC on inclusion of cefazolin in WHO model list of essential medicines

• Memorandum from Dr M. Ryan, Director, EPR re: possibility of inclusion of influenza-specific antivirals to the model list

• Letter from Merck Sharp & Dohme on the ATRIPLA

• Comments on the draft Rational Use of Medicines (RUM) Resolution

• Comments on application for addition: 25mg medroxyprogesterone acetate + 5mg estradiol cypionate combined injectable contraceptive

• Comments on: IAHPC list of essential medicines for palliative care

• Comments about critically important antibiotic proposal

• Comments on Advice on draft resolution on rational use of medicines

• Comments on application for inclusion of phenytoin for childhood epilepsy

• Comments on application for inclusion of carbamazepine for childhood epilepsy

• Comments on application for inclusion of sodium valproate for childhood epilepsy

• Comments on application for inclusion of efavirenz, emtricitabine and tenofovir disoproxil fumarate fixed-dose combination tablet.

• Comments on application for the removal of vaccines the WHO essential drug list

• Comments on Proposal for Formal Sub-committee of the Expert Committee on the selection and use of essential medicines

• Comments about Antitrypanosomal Medicines section review

• Dafra: Stability of the artemether/lumefantrine suspension

• Expert's comment on orphan medicines

• Formulary text for: isoniazid; pyrazinamide; zidovudine+lamivudine; lamivudine+stavudine+nevirapine; zidovudine+lamivudine+nevirapine

• IUPHAR comments on WHO Proposal for formal sub-committee of the Expert Committee on the Selection and Use of Essential Medicines

• MSF: Request for non-inclusion to the 15th WHO M EML of lamivudine/stavudine/nevirapine, lamivudine/zidovudine/nevirapine and lamivudine/zidovudine fixed-dose combinations tablets

• Review of ophthalmology section of WHO model list of essential medicines

• Reviewer's check list: Lamivudine in combination with zidovudine

• Reviewer's check list: Stavudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection

• Reviewer's check list: Zidovudine/lamivudine/nevirapine fixed-dose combination tablets for the treatment of HIV-1 infection

• Secretariat addendum to discussion paper on fixed dose combinations

• Secretariat proposed dosage form and strength review

• WHO Comments to support the 'Application for the re-instatement of Polyvalent Human Immunoglobulin  in the WHO Model List of Essential Medicines'

Back to the EML Expert Committee Resources Menu

See also the Essential Medicines Library

Last update:29-Feb-2008  ?World Health Organization 2007. All rights reserved